Navigation Links
SUPERaseIn from Ambion

ProductsSUPERaseIn from Ambion
Company Ambion
Item SUPERaseIn
Price $92.00
Description SUPERaseIn RNase Inhibitor (patent pending) is a protein based inhibitor of nonhuman origin that noncovalently binds and inhibits the most common and troublesome RNases including RNase A, B, C, 1 and T1. SUPERaseIn can be used in any application where RNase contamination could be problematic. It is ideal for in vitro transcription and translation, cDNA synthesis, RT-PCR, and preparation of RNase-free antibodies. Because it inhibits a broader range of RNases than traditional RNase inhibitors, SUPERaseIn is the most effective RNase inhibitor available providing a higher level of protection against degradation.

The most widely used RNase inhibitor is placental ribonuclease inhibitor (RIP). SUPERaseIn is distinct from RIP in that it has a more robust interaction with RNases, does not release active RNases in the absence of DTT, and inhibits a broader range of RNases. While placental ribonuclease inhibitors are effective only against RNase A type enzymes, SUPERaseIn also inhibits RNase 1 and T1. SUPERaseIn does not interfere with other enzymes such as RNA polymerases, reverse transcriptase or Taq polymerase. Additionally, SUPERaseIn is active up to 65C and for a pH range of 5.5 to 8.5.

Info AmbionAmbion
2130 Woodward
Austin, TX 78744

Call Ambion to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-512-795-4221
Customer Service: 512-651-0200
Fax Number: 512-651-0201
Web Site:
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. SUPERaseIn from Ambion
2. Silencer siRNA Starter Kit from Ambion
3. SlideHyb Glass Array Hybridization Buffer #1 from Ambion
4. mirVana™ miRNA Bioarray Essentials Kit from Ambion
5. SlideHyb Glass Array Hybridization Buffer #1 from Ambion
6. siPORT NeoFX Transfection Agent 1 ml from Ambion
7. siPORT NeoFX Transfection Agent from Ambion
8. DNase I (RNase-free) (2 U/l) from Ambion
9. TURBO DNase (2 U/l) from Ambion
10. Guanylyltransferase (5 U/l) from Ambion
11. 96 well Magnetic-Ring Stand 1 each from Ambion
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Goat polyclonal to DRAK2...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
Biology Products:
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... Pleasant Prairie, WI (PRWEB) , ... June 23, ... ... sciences consultancy focused on quality, regulatory and technical consulting, provides a free ... webinar is presented on July 13, 2016 at 12pm CT at no charge. ...
Breaking Biology Technology: